| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Erenumab |
| Brand | Aimovig® |
| Indication | For the treatment of chronic and episodic migraine in adults who have at least 4 migraine days per month when initiating treatment with erenumab. |
| Assessment Process | |
| Rapid review commissioned | 19/07/2018 |
| Rapid review completed | 15/08/2018 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of erenumab compared with the current standard of care |
| Full pharmacoeconomic assessment commissioned by HSE | 28/08/2018 |
| Pre-submission consultation with Applicant | 24/09/2018 |
| Full submission received from Applicant | 22/01/2019 |
| Preliminary review sent to Applicant | 01/04/2019 |
| NCPE assessment re-commenced | 01/05/2019 |
| Factual accuracy sent to Applicant | 31/07/2019 |
| NCPE assessment re-commenced | 06/08/2019 |
| NCPE assessment completed | 30/09/2019 |
| NCPE assessment outcome | Chronic Migraine: The NCPE recommends that erenumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.* Episodic Migraine: The NCPE recommends that erenumab not be considered for reimbursement.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations September 2021
